Table 2 Grade 3–4 acute and late toxic effects
Adverse events | PET/CT-guided DP-IMRT | CT-based IMRT | p value* |
|---|---|---|---|
No. of patients (%) | No. of patients (%) | ||
Acute adverse events | |||
 Anemia | 1 (1.0) | 2 (1.8) | 0.54 |
 Neutropenia | 8 (7.9) | 11 (9.8) | 0.63 |
 Leukopenia | 15 (14.9) | 18 (16.1) | 0.85 |
 Thrombocytopenia | 1 (1.0) | 1 (0.9) | 0.73 |
 Liver dysfunction | 0 | 0 | .. |
 Nephrotoxicity | 0 | 0 | .. |
 Nausea | 14 (13.9) | 17 (15.2) | 0.85 |
 Vomiting | 10 (9.9) | 13 (11.6) | 0.83 |
 Mucositis | 31 (30.7) | 34 (32.1) | 0.77 |
 Dermatitis | 9 (8.9) | 12 (10.7) | 0.82 |
 Dysphagia or odynophagia | 3 (2.9) | 5 (4.5) | 0.72 |
 Dry mouth | 3 (2.9) | 6 (5.3) | 0.50 |
 Ototoxicity | 0 | 1 (0.9) | 0.53 |
Late adverse events | |||
 Skin fibrosis | 0 | 1 (0.9) | 0.53 |
 Dry mouth | 0 | 0 | .. |
 Ototoxicity | 0 | 1 (0.9) | 0.53 |
 Trismus | 0 | 0 | .. |
 Nasopharyngeal ulceration | 0 | 0 | .. |